Leinfelden-Echterdingen, 22.11.2023.
MVS Pharma GmbH announced today the signing of the NDA for cooperation with an Indian drug manufacturer, in the distribution of Amoxicillin 250mg/5ml dry juice. This substance will be used for the preparation of an oral suspension, which belongs to the group of antibiotics listed on the Federal Ministry of Health’s “Urgent List of Pediatric Medicines Fall-Winter 2023/2024” and for which there are currently delivery bottlenecks.
The next step is for the Indian Pharmaceutical Products Control Authority to grant MVS Pharma GmbH an export license for Amoxicillin 250mg/5ml under the brand name Elvantine®-Amoxicillin BP 250mg/5ml.
Stay up to date and read on the official website – www.mvs-pharma.com how MVS Pharma GmbH is getting closer to the goal of importing Elvantine®-Amoxicillin BP 250mg/5 ml to Germany step by step and thus making a contribution to reducing delivery bottlenecks.
About MVS Pharma GmbH
MVS Pharma GmbH is a forward-thinking pharmaceutical company based in Leinfelden-Echterdingen, Germany, with a branch in India. Founded in 2021, the company specializes in providing high-quality, safe, and effective pharmaceutical solutions to address critical health challenges. MVS Pharma is driven by its commitment to patient safety, transparency, and regulatory compliance.
MVS Pharma is a manufacturer, with its own team of professionals and experts in each field. And because the main goal of the company is the well-being of its customers, it makes sure to create all its products using only the best raw materials, free from heavy metals, pesticides, plastic, etc. In addition, MVS Pharma is also working on further clinical research into rose hips for a natural treatment of osteoarthritis and pure fish oil, purified from heavy metals, protected against oxidation, and packaged under 7 other steps, which will guarantee its high quality.
For press & media inquiries, please contact:
Mihaela Ahchieva
Head of Public Relations
MVS Pharma GmbH
mihaela.ahchieva@mvs-pharma.com
